The genomic landscape of pediatric cancers: Implications for diagnosis and treatment.

E Alejandro Sweet-Cordero, Jaclyn A Biegel
Author Information
  1. E Alejandro Sweet-Cordero: Department of Pediatrics, Division of Hematology and Oncology, University of California, San Francisco, CA 94158, USA. jbiegel@chla.usc.edu alejandro.sweet-cordero@ucsf.edu.
  2. Jaclyn A Biegel: Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, and Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA. jbiegel@chla.usc.edu alejandro.sweet-cordero@ucsf.edu. ORCID

Abstract

The past decade has witnessed a major increase in our understanding of the genetic underpinnings of childhood cancer. Genomic sequencing studies have highlighted key differences between pediatric and adult cancers. Whereas many adult cancers are characterized by a high number of somatic mutations, pediatric cancers typically have few somatic mutations but a higher prevalence of germline alterations in cancer predisposition genes. Also noteworthy is the remarkable heterogeneity in the types of genetic alterations that likely drive the growth of pediatric cancers, including copy number alterations, gene fusions, enhancer hijacking events, and chromoplexy. Because most studies have genetically profiled pediatric cancers only at diagnosis, the mechanisms underlying tumor progression, therapy resistance, and metastasis remain poorly understood. We discuss evidence that points to a need for more integrative approaches aimed at identifying driver events in pediatric cancers at both diagnosis and relapse. We also provide an overview of key aspects of germline predisposition for cancer in this age group.

References

  1. Cancer Discov. 2012 May;2(5):458-71 [PMID: 22588883]
  2. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):350-66 [PMID: 25169151]
  3. J Clin Oncol. 2015 Feb 20;33(6):602-9 [PMID: 25584008]
  4. Clin Cancer Res. 2017 Sep 15;23(18):5329-5338 [PMID: 28600472]
  5. Clin Cancer Res. 2017 Jun 1;23(11):e23-e31 [PMID: 28572264]
  6. Acta Neuropathol. 2018 Aug;136(2):227-237 [PMID: 30019219]
  7. Nature. 2013 Jul 11;499(7457):214-218 [PMID: 23770567]
  8. Crit Rev Oncol Hematol. 2016 Aug;104:30-41 [PMID: 27263935]
  9. Haematologica. 2014 Nov;99(11):1653-62 [PMID: 25420281]
  10. Pediatr Blood Cancer. 2017 Mar;64(3): [PMID: 27748023]
  11. J Clin Invest. 2012 Aug;122(8):2983-8 [PMID: 22797305]
  12. JAMA. 2015 Sep 1;314(9):913-25 [PMID: 26325560]
  13. Cancer Discov. 2017 Aug;7(8):818-831 [PMID: 28572459]
  14. Science. 2008 Nov 28;322(5906):1377-80 [PMID: 19039135]
  15. J Clin Oncol. 2016 Jul 1;34(19):2206-11 [PMID: 27001570]
  16. J Clin Oncol. 2019 Feb 20;37(6):513-524 [PMID: 30592640]
  17. Clin Cancer Res. 2017 Jun 1;23(11):e6-e13 [PMID: 28572262]
  18. Nat Genet. 2013 Mar;45(3):279-84 [PMID: 23334666]
  19. Lancet Oncol. 2018 Jun;19(6):768-784 [PMID: 29778738]
  20. Lancet Oncol. 2017 Jun;18(6):719-731 [PMID: 28410997]
  21. Science. 2013 Mar 29;339(6127):1546-58 [PMID: 23539594]
  22. Science. 2019 Mar 15;363(6432):1125 [PMID: 30872493]
  23. Nat Commun. 2015 Mar 19;6:6604 [PMID: 25790293]
  24. Discov Med. 2018 Aug;26(141):51-60 [PMID: 30265855]
  25. N Engl J Med. 2015 Dec 10;373(24):2336-2346 [PMID: 26580448]
  26. Nat Commun. 2018 Sep 27;9(1):3962 [PMID: 30262806]
  27. Nat Genet. 2017 Aug;49(8):1211-1218 [PMID: 28671688]
  28. Clin Cancer Res. 2017 Jun 1;23(11):e1-e5 [PMID: 28572261]
  29. Clin Cancer Res. 2017 Jun 15;23(12):e46-e53 [PMID: 28620004]
  30. Nat Genet. 2011 Mar;43(3):237-41 [PMID: 21297632]
  31. Clin Pharmacol Ther. 2017 Dec;102(6):897-902 [PMID: 28795399]
  32. Mol Cell Pediatr. 2018 Aug 31;5(1):6 [PMID: 30171420]
  33. Nature. 2016 Jan 21;529(7586):351-7 [PMID: 26760213]
  34. Leukemia. 2015 Aug;29(8):1656-67 [PMID: 25917266]
  35. Nat Commun. 2018 Aug 17;9(1):3292 [PMID: 30120226]
  36. Clin Cancer Res. 2011 Jan 1;17(1):31-8 [PMID: 21208904]
  37. Genes Chromosomes Cancer. 2018 Mar;57(3):123-139 [PMID: 29205637]
  38. Nature. 2017 Jul 19;547(7663):311-317 [PMID: 28726821]
  39. Nat Genet. 2015 Dec;47(12):1411-4 [PMID: 26523776]
  40. Br J Cancer. 2018 Aug;119(5):615-621 [PMID: 30131550]
  41. Clin Cancer Res. 2017 Jul 1;23(13):e98-e106 [PMID: 28674118]
  42. Nat Commun. 2014 Mar 24;5:3469 [PMID: 24662245]
  43. Nature. 2018 Jan 25;553(7689):511-514 [PMID: 29342136]
  44. Nature. 2018 Mar 15;555(7696):371-376 [PMID: 29489755]
  45. Nature. 2018 Mar 22;555(7697):469-474 [PMID: 29539639]
  46. Lancet Oncol. 2016 Sep;17(9):1295-305 [PMID: 27501770]
  47. Cell. 2011 Jan 7;144(1):27-40 [PMID: 21215367]
  48. Pediatr Blood Cancer. 2011 Jan;56(1):7-15 [PMID: 21108436]
  49. Nat Genet. 2012 May 29;44(6):619-22 [PMID: 22641210]
  50. Nature. 1998 Jul 9;394(6689):203-6 [PMID: 9671307]
  51. Nat Genet. 2015 Aug;47(8):864-71 [PMID: 26121087]
  52. Acta Neuropathol. 2012 Apr;123(4):465-72 [PMID: 22134537]
  53. J Clin Oncol. 2010 Apr 20;28(12):1995-2001 [PMID: 20308654]
  54. Nat Genet. 2017 Oct;49(10):1487-1494 [PMID: 28825729]
  55. Nature. 2011 Mar 10;471(7337):235-9 [PMID: 21390130]
  56. Cell. 2013 Apr 25;153(3):666-77 [PMID: 23622249]
  57. Cell. 2018 Apr 5;173(2):355-370.e14 [PMID: 29625052]
  58. Nat Rev Cancer. 2015 Jun;15(6):371-81 [PMID: 25998716]
  59. ESMO Open. 2016 Mar 18;1(2):e000023 [PMID: 27843590]
  60. Pediatr Blood Cancer. 2019 Mar;66(3):e27546 [PMID: 30393974]
  61. Nature. 2014 Feb 27;506(7489):451-5 [PMID: 24553141]
  62. Oncogene. 2015 Oct 8;34(41):5207-15 [PMID: 25639868]
  63. Nat Genet. 2018 Jul;50(7):944-950 [PMID: 29867221]
  64. JAMA Pediatr. 2018 May 1;172(5):476-481 [PMID: 29554172]
  65. J Clin Oncol. 2017 Jul 20;35(21):2346-2354 [PMID: 28640705]
  66. Nat Med. 2018 Jan;24(1):103-112 [PMID: 29227476]
  67. Science. 2019 Mar 15;363(6432):1175-1181 [PMID: 30872517]
  68. Nature. 2018 Mar 15;555(7696):321-327 [PMID: 29489754]
  69. JAMA Oncol. 2016 May 01;2(5):616-624 [PMID: 26822237]
  70. Cancer. 2016 Apr 1;122(7):1017-28 [PMID: 26849082]
  71. Cell. 2017 Nov 16;171(5):1042-1056.e10 [PMID: 29056344]
  72. Lancet Oncol. 2018 Jun;19(6):785-798 [PMID: 29753700]
  73. Nat Genet. 2016 Mar;48(3):273-82 [PMID: 26829751]
  74. Nature. 2012 Jan 29;482(7384):226-31 [PMID: 22286061]
  75. Nature. 2018 Jan 4;553(7686):101-105 [PMID: 29258295]
  76. Cancer. 2018 Nov 1;124(21):4168-4180 [PMID: 30255939]
  77. Nat Genet. 2013 Jun;45(6):592-601 [PMID: 23644491]
  78. J Clin Oncol. 2009 Nov 1;27(31):5175-81 [PMID: 19805687]
  79. Clin Cancer Res. 2017 Jun 15;23(12):e62-e67 [PMID: 28620006]
  80. Nature. 2012 Jan 11;481(7380):157-63 [PMID: 22237106]
  81. N Engl J Med. 2014 Sep 11;371(11):1005-15 [PMID: 25207766]

Grants

  1. P30 CA014089/NCI NIH HHS
  2. R01 CA211657/NCI NIH HHS

MeSH Term

Adult
Child
DNA Copy Number Variations
Disease Progression
Genes, Neoplasm
Genetic Predisposition to Disease
Genomics
Humans
Mutation
Neoplasm Metastasis
Neoplasms
Oncogene Fusion
Recurrence